MX2020010417A - Inhibidor de ret para uso en tratar cancer que tiene una alteracion de ret. - Google Patents

Inhibidor de ret para uso en tratar cancer que tiene una alteracion de ret.

Info

Publication number
MX2020010417A
MX2020010417A MX2020010417A MX2020010417A MX2020010417A MX 2020010417 A MX2020010417 A MX 2020010417A MX 2020010417 A MX2020010417 A MX 2020010417A MX 2020010417 A MX2020010417 A MX 2020010417A MX 2020010417 A MX2020010417 A MX 2020010417A
Authority
MX
Mexico
Prior art keywords
ret
alteration
treating cancer
inhibitor
ret inhibitor
Prior art date
Application number
MX2020010417A
Other languages
English (en)
Inventor
Beni B Wolf
Raab Erica Evans
Original Assignee
Blueprint Medicines Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Blueprint Medicines Corp filed Critical Blueprint Medicines Corp
Publication of MX2020010417A publication Critical patent/MX2020010417A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Abstract

Se describe en la presente el tratamiento de un sujeto afectado por un cáncer que tiene una alteración de RET activadora al administrar una cantidad efectiva de un inhibidor de RET selectivo, por ejemplo, Compuesto 1 o sales farmacéuticamente aceptables del mismo, incluyendo, por ejemplo, administrar una cantidad de 300 mg a 400 mg del inhibidor de RET selectivo una vez al día.
MX2020010417A 2018-04-03 2019-04-03 Inhibidor de ret para uso en tratar cancer que tiene una alteracion de ret. MX2020010417A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862652284P 2018-04-03 2018-04-03
US201862656297P 2018-04-11 2018-04-11
US201862657605P 2018-04-13 2018-04-13
US201862741683P 2018-10-05 2018-10-05
PCT/US2019/025655 WO2019195471A1 (en) 2018-04-03 2019-04-03 Ret inhibitor for use in treating cancer having a ret alteration

Publications (1)

Publication Number Publication Date
MX2020010417A true MX2020010417A (es) 2021-01-08

Family

ID=66223846

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020010417A MX2020010417A (es) 2018-04-03 2019-04-03 Inhibidor de ret para uso en tratar cancer que tiene una alteracion de ret.

Country Status (22)

Country Link
US (3) US20210100795A1 (es)
EP (2) EP3773589B1 (es)
JP (3) JP7422084B2 (es)
KR (1) KR20200139749A (es)
AU (1) AU2019247766A1 (es)
BR (1) BR112020020273A2 (es)
CA (1) CA3096043A1 (es)
CL (1) CL2020002544A1 (es)
CR (1) CR20200522A (es)
DK (1) DK3773589T3 (es)
FI (1) FI3773589T3 (es)
HR (1) HRP20240124T1 (es)
IL (1) IL277629A (es)
LT (1) LT3773589T (es)
MX (1) MX2020010417A (es)
PE (1) PE20210096A1 (es)
PL (1) PL3773589T3 (es)
PT (1) PT3773589T (es)
RS (1) RS65127B1 (es)
SG (1) SG11202009681YA (es)
SI (1) SI3773589T1 (es)
WO (1) WO2019195471A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10202365B2 (en) 2015-02-06 2019-02-12 Blueprint Medicines Corporation 2-(pyridin-3-yl)-pyrimidine derivatives as RET inhibitors
LT3371171T (lt) 2015-11-02 2024-01-10 Blueprint Medicines Corporation Ret inhibitoriai
KR20200139749A (ko) 2018-04-03 2020-12-14 블루프린트 메디신즈 코포레이션 Ret 변경을 갖는 암을 치료하는 데 사용하는 데 사용하기 위한 ret 억제제
US11666570B2 (en) * 2019-07-11 2023-06-06 The Board Of Trustees Of The Leland Stanford Junior University Diagnosis and regulation of epidermal differentiation and cancer cell activity

Family Cites Families (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0301117A3 (en) 2000-02-17 2004-01-28 Amgen Inc Thousand Oaks Imidazole derivatives kinase inhibitors, their use, process for their preparation and pharmaceutical compositions containing them
BR0312873A (pt) 2002-07-24 2005-06-28 Univ Cincinnati 4-(4-metilpiperazin-1-ilmetil)-n-[4-metil-3-(4-piridin-3-il) pirimidin-2-ilamino)fenil] benzamida para tratamento de doenças associadas com ret cinase mutante
PL1696920T3 (pl) 2003-12-19 2015-03-31 Plexxikon Inc Związki i sposoby opracowywania modulatorów Ret
US8227455B2 (en) 2005-04-18 2012-07-24 Rigel Pharmaceuticals, Inc. Methods of treating cell proliferative disorders
EP1879575A2 (en) 2005-05-09 2008-01-23 Achillion Pharmaceuticals, Inc. Thiazole compounds and methods of use
US20100047777A1 (en) 2005-05-26 2010-02-25 The Johns Hopkins University Methods for identifying mutations in coding and non-coding dna
WO2007023382A2 (en) 2005-08-25 2007-03-01 Pfizer Inc. Pyrimidine amino pyrazole compounds, potent kinase inhibitors
EP1978958A4 (en) 2006-01-24 2009-12-02 Merck & Co Inc INHIBITION OF TYROSINE KINASE RET
CN101443009A (zh) 2006-05-18 2009-05-27 卫材R&D管理有限公司 针对甲状腺癌的抗肿瘤剂
US20090048214A1 (en) 2006-11-15 2009-02-19 Rigel Pharmaceuticals, Inc Methods for Treating Renal Tumors Using 2, 4-Pyrimidinediamine Drug and Prodrug Compounds
WO2009003136A1 (en) 2007-06-26 2008-12-31 Rigel Pharmaceuticals, Inc. Substituted pyrimidine-2, 4 -diamines for treating cell proliferative disorders
AR067478A1 (es) 2007-07-09 2009-10-14 Astrazeneca Ab Compuestos derivados de morfolina pirimidina
EP2178861B1 (en) 2007-07-19 2014-08-20 Merck Sharp & Dohme Corp. Heterocyclic amide compounds as protein kinase inhibitors
WO2009100536A1 (en) 2008-02-15 2009-08-20 Methylgene Inc. Inhibitors of kinase activity with 1,2-di-cyclyl substituted alkyne structures
CA2730190A1 (en) 2008-07-14 2010-01-21 Queen's University At Kingston Pharmaceutical compositions comprising ret inhibitors and methods for the treatment of cancer
KR20120004467A (ko) 2009-03-24 2012-01-12 엠에스디 가부시키가이샤 오로라 ａ 선택적 억제 작용을 갖는 신규한 아미노피리딘 유도체
KR20120034726A (ko) 2009-06-08 2012-04-12 아브락시스 바이오사이언스, 엘엘씨 트리아진 유도체와 이들의 치료적 용도
US8877924B2 (en) 2009-06-09 2014-11-04 NantBio Inc. Benzyl substituted triazine derivatives and their therapeutical applications
US20120316137A1 (en) 2009-10-30 2012-12-13 Ariad Pharmaceuticals, Inc. Methods and Compositions for Treating Cancer
SG10201407453TA (en) 2009-11-13 2014-12-30 Genosco Kinase inhibitors
CN103764676A (zh) 2011-08-04 2014-04-30 日本国立癌症研究中心 Kif5b基因和ret基因的融合基因、以及以该融合基因为目标的判断癌症治疗有效性的方法
CA2846197C (en) 2011-08-23 2024-01-16 Foundation Medicine, Inc. Kif5b-ret fusion molecules and uses thereof
EP2751112B1 (en) 2011-09-02 2019-10-09 The Regents of The University of California Substituted pyrazolo[3,4-d]pyrimidines and uses thereof
US20130096136A1 (en) 2011-09-30 2013-04-18 Methylgene Inc. Inhibitors of Protein Tyrosine Kinase Activity
US10023855B2 (en) 2011-10-31 2018-07-17 Macrogen, Inc. Fusion protein comprising C-terminal domain of RET protein and use thereof as a diagnosing marker
US8841450B2 (en) 2011-11-09 2014-09-23 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
EP2824099A4 (en) 2012-03-09 2015-11-11 Carna Biosciences Inc NOVEL TRIAZINE DERIVATIVE
JP2015109806A (ja) 2012-03-22 2015-06-18 アステラス製薬株式会社 新規ｒｅｔ融合体の検出法
CN104520296B (zh) 2012-04-25 2016-11-16 拉夸里亚创药株式会社 作为ttx-s阻断剂的吡咯并吡啶酮衍生物
EP2849751A1 (en) 2012-05-10 2015-03-25 Synta Pharmaceuticals Corp. Treating cancer with hsp90 inhibitory compounds
DK2872491T3 (da) 2012-07-11 2021-08-09 Blueprint Medicines Corp Inhibitorer af fibroblastvækstfaktorreceptoren
US20150177246A1 (en) 2012-07-26 2015-06-25 Lsip, Llc Fusion gene of cep55 gene and ret gene
CN104703600A (zh) 2012-09-07 2015-06-10 埃克塞里艾克西斯公司 用于治疗肺腺癌的met、vegfr和ret的抑制剂
ES2692664T3 (es) 2012-09-25 2018-12-04 Chugai Seiyaku Kabushiki Kaisha Inhibidor de RET
JP6326057B2 (ja) 2012-11-07 2018-05-16 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ 置換ピリミジニルおよびピリジニル−ピロロピリジノン、これらの調製のための方法、およびキナーゼ阻害剤としてのこれらの使用
TWI629266B (zh) 2012-12-28 2018-07-11 藍印藥品公司 纖維母細胞生長因子受體之抑制劑
WO2014130810A1 (en) 2013-02-25 2014-08-28 Bristol-Myers Squibb Company C-3 alkyl and alkenyl modified betulinic acid derivatives useful in the treatment of hiv
US9382238B2 (en) 2013-03-15 2016-07-05 Glaxosmithkline Intellectual Property Development Limited Pyridine derivatives as rearranged during transfection (RET) kinase inhibitors
US9499522B2 (en) 2013-03-15 2016-11-22 Blueprint Medicines Corporation Compositions useful for treating disorders related to kit
IN2013MU00848A (es) 2013-03-19 2015-05-01 Glenmark Generics Ltd
WO2015006875A1 (en) 2013-07-18 2015-01-22 Methylgene Inc. Process for the preparation of substituted pyrimidines
CN105658814A (zh) 2013-08-20 2016-06-08 日本国立癌症研究中心 在肺癌中检测出的新型融合基因
US9334263B2 (en) 2013-10-17 2016-05-10 Blueprint Medicines Corporation Compositions useful for treating disorders related to kit
DK3057969T3 (en) 2013-10-17 2018-09-24 Blueprint Medicines Corp COMPOSITIONS USED FOR TREATMENT OF DISEASES RELATED TO ENZYMETE KIT
EP3060560A1 (en) 2013-10-25 2016-08-31 Blueprint Medicines Corporation Inhibitors of the fibroblast growth factor receptor
GB201321146D0 (en) 2013-11-29 2014-01-15 Cancer Rec Tech Ltd Quinazoline compounds
WO2015108992A1 (en) 2014-01-15 2015-07-23 Blueprint Medicines Corporation Heterobicyclic compounds and their use as fgfr4 receptor inhibitors
WO2016022569A1 (en) 2014-08-04 2016-02-11 Blueprint Medicines Corporation Compositions useful for treating disorders related to kit
EP3191450B1 (en) 2014-09-10 2019-04-10 GlaxoSmithKline Intellectual Property Development Limited Pyridone derivatives as rearranged during transfection (ret) kinase inhibitors
BR112017004897A2 (pt) 2014-09-10 2017-12-12 Glaxosmithkline Ip Dev Ltd compostos inovadores como inibidores rearranjados durante a transfecção (ret)
WO2016075224A1 (en) 2014-11-14 2016-05-19 Nerviano Medical Sciences S.R.L. 6-amino-7-bicyclo-7-deaza-purine derivatives as protein kinase inhibitors
US10202365B2 (en) 2015-02-06 2019-02-12 Blueprint Medicines Corporation 2-(pyridin-3-yl)-pyrimidine derivatives as RET inhibitors
CN104844567B (zh) 2015-04-23 2017-03-29 暨南大学 一种中间体1‑(3‑氯‑2‑吡啶基)‑3‑溴‑1h‑5‑吡唑甲酸的合成方法
EA035049B1 (ru) 2015-07-16 2020-04-22 Аррэй Байофарма Инк. СОЕДИНЕНИЯ ЗАМЕЩЕННОГО ПИРАЗОЛО[1,5-a]ПИРИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ RET КИНАЗЫ
AU2016297754A1 (en) 2015-07-24 2018-02-15 Blueprint Medicines Corporation Compounds useful for treating disorders related to KIT and PDGFR
CA2995997A1 (en) 2015-08-26 2017-03-02 Blueprint Medicines Corporation Compounds and compositions useful for treating disorders related to ntrk
CN105255927B (zh) 2015-09-30 2018-07-27 温州医科大学附属第一医院 一种kiaa1217-ret融合基因
MA43163A (fr) 2015-11-02 2018-09-12 Five Prime Therapeutics Inc Polypeptides à domaine extracellulaire cd80 et leur utilisation dans le traitement du cancer
LT3371171T (lt) 2015-11-02 2024-01-10 Blueprint Medicines Corporation Ret inhibitoriai
CA3003899A1 (en) 2015-11-02 2017-05-11 Janssen Pharmaceutica Nv Anti-il1rap antibodies, bispecific antigen binding molecules that bind il1rap and cd3, and uses thereof
SG10201912607SA (en) 2015-11-19 2020-02-27 Blueprint Medicines Corp Compounds and compositions useful for treating disorders related to ntrk
MA43416A (fr) 2015-12-11 2018-10-17 Regeneron Pharma Méthodes pour ralentir ou empêcher la croissance de tumeurs résistantes au blocage de l'egfr et/ou d'erbb3
WO2017145050A1 (en) 2016-02-23 2017-08-31 Glaxosmithkline Intellectual Property Development Limited Pyridylpyridone derivative useful as a ret kinase inhibitor in the treatment of ibs and cancer
US10183928B2 (en) 2016-03-17 2019-01-22 Blueprint Medicines Corporation Inhibitors of RET
SG10202009589UA (en) 2016-04-01 2020-10-29 Signal Pharm Llc Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith
CA3020778A1 (en) 2016-04-15 2017-10-19 Cancer Research Technology Limited Heterocyclic compounds as ret kinase inhibitors
HUE063042T2 (hu) 2016-04-15 2023-12-28 Blueprint Medicines Corp Az aktivin receptorszerû kináz inhibitorai
PL3442535T3 (pl) 2016-04-15 2022-10-24 Cancer Research Technology Limited Związki heterocykliczne jako inhibitory kinazy ret
WO2018017983A1 (en) 2016-07-22 2018-01-25 Blueprint Medicines Corporation Compounds useful for treating disorders related to ret
US10035789B2 (en) 2016-07-27 2018-07-31 Blueprint Medicines Corporation Compounds useful for treating disorders related to RET
US20190192522A1 (en) 2016-09-08 2019-06-27 Blueprint Medicines Corporation Inhibitors of the fibroblast growth factor receptor 4 in combination with cyclin-dependent kinase inhibitors
JP2018052878A (ja) 2016-09-29 2018-04-05 第一三共株式会社 ピリジン化合物
CN106749231B (zh) 2016-10-09 2019-03-01 南京纳丁菲医药科技有限公司 萘啶化合物和药物组合物及它们的应用
JOP20190077A1 (ar) 2016-10-10 2019-04-09 Array Biopharma Inc مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret
TWI704148B (zh) * 2016-10-10 2020-09-11 美商亞雷生物製藥股份有限公司 作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
EP3548007A4 (en) 2016-12-01 2020-08-12 Ignyta, Inc. CANCER TREATMENT METHODS
WO2018136663A1 (en) 2017-01-18 2018-07-26 Array Biopharma, Inc. Ret inhibitors
EP3571203B1 (en) 2017-01-18 2023-06-07 Array BioPharma Inc. Substituted pyrazolo[1,5-a]pyrazine compounds as ret kinase inhibitors
US11040979B2 (en) 2017-03-31 2021-06-22 Blueprint Medicines Corporation Substituted pyrrolo[1,2-b]pyridazines for treating disorders related to KIT and PDGFR
GB201705971D0 (en) 2017-04-13 2017-05-31 Cancer Res Tech Ltd Inhibitor compounds
WO2018213329A1 (en) * 2017-05-15 2018-11-22 Blueprint Medicines Corporation Combinations of ret inhibitors and mtorc1 inhibitors and uses thereof for the treatment of cancer mediated by aberrant ret activity
EP3641776B1 (en) 2017-06-23 2023-10-18 San Diego State University Research Foundation Atropisomerism for enhanced kinase inhibitor selectivity
CN109180677A (zh) 2017-06-30 2019-01-11 厦门大学 取代芳基醚类化合物、其制备方法、药用组合物及其应用
DK3649260T3 (en) 2017-07-07 2022-08-08 Nipd Genetics Public Company Ltd Target-beriget multiplekset parallel analyse til vurdering af tumorbiomarkører
CN107980784B (zh) 2017-12-13 2020-05-26 中国农业大学 5-氨基吡唑类化合物在调节植物生长方面的应用
JP7194188B2 (ja) 2017-12-19 2022-12-21 ターニング・ポイント・セラピューティクス・インコーポレイテッド 疾患を治療するための大環状化合物
TWI802635B (zh) 2018-01-18 2023-05-21 美商亞雷生物製藥股份有限公司 作為ｒｅｔ激酶抑制劑之經取代吡咯并[2,3-d]嘧啶化合物
US11524963B2 (en) 2018-01-18 2022-12-13 Array Biopharma Inc. Substituted pyrazolo[3,4-d]pyrimidines as RET kinase inhibitors
JP6997876B2 (ja) 2018-01-18 2022-02-04 アレイ バイオファーマ インコーポレイテッド Ｒｅｔキナーゼ阻害剤としての置換ピラゾリル［４，３－ｃ］ピリジン化合物
CN108341782A (zh) 2018-03-30 2018-07-31 南京哈柏医药科技有限公司 3-氨基-5-甲基吡唑的合成工艺
KR20200139749A (ko) 2018-04-03 2020-12-14 블루프린트 메디신즈 코포레이션 Ret 변경을 갖는 암을 치료하는 데 사용하는 데 사용하기 위한 ret 억제제
US20210308134A1 (en) 2018-08-10 2021-10-07 Blueprint Medicines Corporation Treatment of egfr-mutant cancer
CN111362923A (zh) 2020-03-25 2020-07-03 魏威 制备ret抑制剂普拉塞替尼的方法、以及普拉塞替尼的中间体及其制备方法
CN111440151A (zh) 2020-03-25 2020-07-24 魏威 制备抗肿瘤药普拉赛替尼的方法
EP4157230A1 (en) 2020-05-29 2023-04-05 Blueprint Medicines Corporation Pralsetinib pharmaceutical compositions
MX2022014858A (es) 2020-05-29 2023-02-23 Blueprint Medicines Corp Formas solidas de pralsetinib.
IL303286A (en) 2020-12-04 2023-07-01 Blueprint Medicines Corp A method for preparing perletinib

Also Published As

Publication number Publication date
PT3773589T (pt) 2024-02-06
CL2020002544A1 (es) 2021-06-11
IL277629A (en) 2020-11-30
JP2021520349A (ja) 2021-08-19
US20220175773A1 (en) 2022-06-09
US11872192B2 (en) 2024-01-16
DK3773589T3 (da) 2024-01-29
CR20200522A (es) 2021-02-17
RU2020135917A (ru) 2022-05-04
RS65127B1 (sr) 2024-02-29
BR112020020273A2 (pt) 2021-04-06
US20210100799A1 (en) 2021-04-08
JP2023165937A (ja) 2023-11-17
KR20200139749A (ko) 2020-12-14
CA3096043A1 (en) 2019-10-10
EP4353317A2 (en) 2024-04-17
SG11202009681YA (en) 2020-10-29
PE20210096A1 (es) 2021-01-12
WO2019195471A1 (en) 2019-10-10
AU2019247766A1 (en) 2020-10-15
SI3773589T1 (sl) 2024-03-29
US11273160B2 (en) 2022-03-15
EP3773589A1 (en) 2021-02-17
US20210100795A1 (en) 2021-04-08
HRP20240124T1 (hr) 2024-04-12
JP2022022391A (ja) 2022-02-03
JP7422084B2 (ja) 2024-01-25
PL3773589T3 (pl) 2024-04-02
FI3773589T3 (fi) 2024-02-01
LT3773589T (lt) 2024-02-12
US20210085680A1 (en) 2021-03-25
EP3773589B1 (en) 2023-11-01

Similar Documents

Publication Publication Date Title
MX2020010417A (es) Inhibidor de ret para uso en tratar cancer que tiene una alteracion de ret.
SG10201810401RA (en) Pharmaceutical combinations for treating cancer
PH12015502691A1 (en) Use of high dose pridopidine for treating huntington's disease
MX2017000612A (es) Inhibidores de tirosina quinasa del bazo (syk).
PH12020551597A1 (en) Treatment of hidradenitis suppurativa using jak inhibitors
NZ714963A (en) Compositions and methods for treating anemia
MX2018006674A (es) Tratamiento de cancer usando 2-desoxi-2-fluoro-l-fucosa en combinacion con un inhibidor del punto de control.
PH12016502352A1 (en) Pharmaceutical composition
WO2020033838A3 (en) Treatment of egfr-mutant cancer
PH12016502353A1 (en) Pharmaceutical composition
WO2018102687A3 (en) Combination therapy for treating cancer
PH12021550047A1 (en) USE OF sGC STIMULATORS FOR THE TREATMENT OF MITOCHONDRIAL DISORDERS
MX2021006156A (es) Compuestos utiles en la terapia para el vih.
MX2021002322A (es) Nuevos metodos.
MX2020010697A (es) Kit, composicion y terapia de combinacion para el sindrome del cromosoma x fragil.
MX2019002369A (es) Compuestos para el tratamiento de enfermedades asociadas con una disfuncion mitocondrial.
MX2008002456A (es) Uso de ambroxol para el tratamiento de infecciones por rinovirus.
MX2018010223A (es) Terapia combinada para tratamiento de cancer de ovario.
ZA201905212B (en) Rescue treatment of post operative nausea and vomiting
SG10201809673RA (en) Treatment of androgen deprivation therapy associated symptoms
MX2020007817A (es) Prevención y tratamiento del trastorno del sueño.
CL2021003303A1 (es) Tratamiento para sinucleinopatías.
MX2022000729A (es) Terapia de combinacion para el tratamiento del cancer.
EA202193276A1 (ru) Способы лечения холангиокарциномы
MX2022000426A (es) Telmisartan para el tratamiento de la hipertension en perros.